Evidence map›Paper›PMID 29311081›Full record

ArticleAntimicrobial agents and chemotherapy2018

Antimicrobial Activity of Ibuprofen against Cystic Fibrosis-Associated Gram-Negative Pathogens.

Parth N Shah, Kimberly R Marshall-Batty, Justin A Smolen, Jasur A Tagaev, Qingquan Chen, Christopher A Rodesney, Henry H Le, Vernita D Gordon, David E Greenberg, Carolyn L Cannon

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 60 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. The anti-inflammatory drug celecoxib is metabolized by Pseudomonas aeruginosa CYP107S1 in vitro and in vivo.Drug metabolism and disposition: the biological fate of chemicals · 2025
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. AnJournal of biomolecular structure & dynamics · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Parth N Shah *Department of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, College Station, Texas, USA.
Kimberly R Marshall-Batty *Department of Internal Medicine and Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Justin A SmolenDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, College Station, Texas, USA.
Jasur A TagaevDepartment of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Qingquan ChenDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, College Station, Texas, USA.
Christopher A RodesneyCenter for Nonlinear Dynamics and Department of Physics, The University of Texas at Austin, Austin, Texas, USA.
Henry H LeCenter for Nonlinear Dynamics and Department of Physics, The University of Texas at Austin, Austin, Texas, USA.
Vernita D GordonCenter for Nonlinear Dynamics and Department of Physics, The University of Texas at Austin, Austin, Texas, USA.
David E GreenbergDepartment of Internal Medicine and Microbiology, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Carolyn L CannonDepartment of Microbial Pathogenesis and Immunology, Texas A&M University Health Science Center, College Station, Texas, USA cannon@medicine.tamhsc.edu.
Texas A&M Health Science Center · USThe University of Texas at Austin · USThe University of Texas Southwestern Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical trials have demonstrated the benefits of ibuprofen therapy in cystic fibrosis (CF) patients, an effect that is currently attributed to ibuprofen's anti-inflammatory properties. Yet, a few previous reports demonstrated an antimicrobial activity of ibuprofen as well, although none investigated its direct effects on the pathogens found in the CF lung, which is the focus of this work. Determination of ibuprofen's

Indexed as

AnimalsBiofilmsBronchoalveolar Lavage FluidBurkholderiaCystic FibrosisGram-Negative BacteriaIbuprofenLungMaleMiceMice, Inbred C57BLNanoparticlesPseudomonas aeruginosaIbuprofenantimicrobialBurkholderia spp.cystic fibrosisibuprofennanoparticlesPseudomonas aeruginosa

Identifiers

PMID29311081
PMCPMC5826130
OpenAlexW2782418238

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.